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Abstract
Objectives and Background: Tissue factor (TF) contributes to thrombosis following plaque
disruption in acute coronary syndromes (ACS). Aim of the study was to investigate the impact of
plasma TF activity on prognosis in patients with ACS.
Methods and Results: One-hundred seventy-four patients with unstable Angina pectoris (uAP)
and 112 patients with acute myocardial infarction (AMI) were included with a mean follow up time
of 3.26 years. On admission, plasma TF activity was assessed. Patients were categorized into 2
groups: a high-TF activity group with TF >24 pmol/L and low TF activity group with TF ≤ 24 pmol/
L. Fifteen cardiovascular deaths occurred in the uAP group and 16 in the AMI group. In AMI TF
activity was 24,9 ± 2,78 pmol/l (mean ± SEM) in survivors and 40,9 ± 7,96 pmol/l in nonsurvivors
(P = 0.024). In uAP no differences were observed (25.0 ± 8.04 pmol/L nonsurvivors vs. 25.7 ± 2.14
pmol/L survivors; P = 0.586). Kaplan-Meier estimates of survival at 3.26 years regarding TF activity
in AMI were 81.3% and 92.2% with an hazard ratio of 3.02 (95% CI [1.05–8.79], P = 0.03). The Cox
proportional hazards model adjusting for correlates of age and risk factors showed that plasma TF
activity was an independent correlate of survival (hazard ratio 9.27, 95% CI [1.24–69.12], P = 0.03).
In an additional group of patients with uAP and AMI, we identified circulating microparticles as the
prevailing reservoir of plasma TF activity in acute coronary syndromes.
Conclusion: Systemic TF activity in AMI has an unfavorable prognostic value and as a marker for
dysregulated coagulation may add to predict the atherothrombotic risk.
Introduction
Atherothrombosis, characterized by a disruption of
atherosclerotic lesions superimposed with thrombus for-
mation, is the major cause of acute coronary syndromes
(ACS) and cardiovascular death. Tissue factor (TF) as the
cellular initiator of the extrinsic coagulation cascade plays
a key role in intravascular thrombus formation by allos-
terically activating factor VII (FVII). Over the last decades
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it has been shown that, in addition to intravascular TF, cir-
culating TF is implicated in arterial and venous thrombo-
sis [1-5]. Current studies have shown that plasma TF is
comprised of: a) TF associated with microparticles (MP)
and b) an alternatively spliced TF variant that lacks the
transmembrane domain [6]. In living mice this plasma or
blood-borne TF accumulates in newly formed thrombi via
monocyte-derived MP and contributes to thrombus
growth and propagation [2,7]. Several studies have dem-
onstrated increased levels of circulating TF in patients
with unstable Angina pectoris (uAP) and acute myocar-
dial infarction (AMI) [8-12]. Therefore, it has long been
speculated that, in cases with no plaque rupture or only
fractional superficial erosion, thrombus formation may
depend on circulating levels of TF. Consistent with this
idea, several studies suggest that the levels of circulating
TF and other haemostatic biomarkers may correlate to
adverse cardiovascular events and mortality in patients
with ACS [13-17]. However, all these data are based on
immunoreactive measurements and provide no evidence
that circulating TF in ACS is functional or is capable of
contributing to systemic hypercoagulability. To date, data
addressing plasma TF activity are lacking. Since TF antigen
measurements do not necessarily reflect the functional
capacity and integrity of TF, measuring TF activity might
be a better approach for stratifying cardiovascular risk.
Therefore, aim of the present study was to investigate
plasma TF activity in patients with ACS and evaluate its




This prospective study enrolled 286 consecutive patients
that were referred to the hospital between July 2001 and
February 2002 for acute coronary syndromes. The diagno-
sis of AMI was established by the presence of chest pain
lasting >20 minutes associated with electrocardiographic
and enzymatic changes (Peak CK ≥ 300 U/l). Electrocardi-
ographic changes included: an ST-segment elevation of at
least 0.1 mV in two or more limb leads, an elevation of at
least 2 mV in two or more contiguous precordial leads on
the surface electrocardiogram, or a new-onset left bundle
branch block. Unstable Angina was defined as a crescendo
pattern of chest pain at rest with documented non-specific
electrocardiographic changes including: a transient ST seg-
ment depression or elevation of at least 0.1 mV in at least
2 contiguous electrocardiographic leads or a T wave inver-
sion. Patients with interfering non-cardiac diseases and
malignancies were not included in the study. On admis-
sion, blood was drawn from all subjects under standard-
ized conditions and plasma samples were stored at -80°C
until analysis. All patients underwent urgent coronary
angiography for percutaneous coronary intervention
(PCI). The study protocol was approved by the institu-
tional ethics committee and informed consent was
obtained from all subjects.
To analyze the sources of circulating TF activity, an addi-
tional group of 36 consecutive patients with uAP and AMI
were recruited between December 2005 and November
2006. A control group comprised 28 patients with stable
angina (sAP) undergoing elective PCI.
Biochemical and microparticle analysis
Plasma TF activity was measured with an FXa generation
assay (Actichrome TF, American Diagnostica; Detection
treshold 2 pM, intra-assay variabilities <10%; inter-assay
variabilities <10%). To inhibit endogenous TFPI TF activ-
ity was measured using an FXa generation assay in the
absence and presence of 100 μg/ml rabbit anti-TFPI-1 IgG
(kindly provided by Dr. W. Ruf) or nonimmune rabbit
IgG (Sigma). TF activity in the presence of anti-TFPI mAbs
represents the total TF activity in the plasma. TF activity
associated with circulating MP was measured by first iso-
lating MP by antibody capture and then analyzing FXa
generation using a commercial available assay (Acti-
chrome®Microparticle activity #817, American diagnostic;
Detection treshold ≤ 0,05 nM, intra-assay variabilities 3–
8%; inter-assay variabilities 5–10%). Plasma TF antigen
was measured by immunoassay (Imubind Tissue Factor
ELISA kit, American Diagnostica; Detection treshold 1,4
pM, intra-assay variabilities 4,5%; inter-assay variabilities
7,5%).
Serum concentrations of creatine kinase, C-reactive pro-
tein (CRP), fibrinogen, and brain natriuretic protein
(BNP) (Roche NT-pro-BNP sandwich electrochemilumi-
nescent assay, Roche Diagnostics, Mannheim, Germany)
were determined in routine clinical chemistry laboratory
analyses.
For analysis of circulating MP, platelet free plasma (PFP)
was immediately snap frozen in liquid nitrogen and
stored at -80°C until use. To separate MP from PFP, aliq-
uots of 250 μl were centrifuged for 60 min at 100,000 × g;
then 225 μl of the supernatant was decanted and stored
for further analysis. MP were resuspended in the remain-
ing 25 μl. Flowcytometric analyses of MP suspensions
were performed according to the manufacturer's instruc-
tions using annexin V Alexa Fluor® 568 in an appropriate
buffer (Boehringer Mannheim, Germany) and either spe-
cific monoclonal antibodies (mAb) or isotype-matched
control antibodies. Antibodies were labeled with fluores-
ceinisothiocyonate (FITC), peridinin-chlorophyll-protein
complex (PerCP), or Allophycocyanin (APC) and
included: FITC-conjugated anti-TF antibody (American
diagnostic), CD41 PerCP (Coulter), and CD 66 APC (Bec-
tonDickinson). Before FACS analysis was performed, a
defined number of latex beads (LB30, Sigma) were addedThrombosis Journal 2009, 7:11 http://www.thrombosisjournal.com/content/7/1/11
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to the samples in order to calculate the absolute amount
of MPs. Analysis was stopped when 5000 beads were
counted.
Clinical follow-up and endpoint definition
All enrolled patients were contacted for follow-up with a
mean of 3.26 years after the percutaneous coronary inter-
vention. The primary outcome measures of the study
were: cardiovascular mortality, which included a) fatal
myocardial infarction and b) ventricular arrhythmias with
heart failure as a consequence of MI, and all cause mortal-
ity.
Statistical analysis
Discrete variables were expressed as counts (%) and com-
pared by chi-square or Fisher's exact test. Continuous var-
iables were expressed as mean ± S.D. and compared by the
Wilcoxon's rank sum test. The Youden-index was used to
determine statistically reliable cut-off value of TF by max-
imizing the sum of sensitivity and specificity in reference
to observed survival state. In this term, area under the
ROC-curve (AUC) was reported to assess overall prognos-
tic performance of plasma TF activity. Further, the corre-
sponding 95% confidence interval of AUC was reported
indicating statistically significant predictive capability if
the critical value of 0.5 is not included. Spearman-Rho
correlation coefficient was used to identify correlates of TF
activity. Survival analysis was performed by applying the
Kaplan-Meier method. Differences in survival were
assessed with log rank test. Cox's proportional hazard
model was used to assess the independent association of
TF activity with mortality. All statistical analyses were per-




Of the 286 patients enrolled in the study, 112 presented
with AMI and 174 were classified as uAP. During the fol-
low up 16 cardiovascular deaths and 8 non-cardiovascular
deaths were reported among patients with AMI; similarly,
15 cardiovascular deaths and 9 non-cardiovascular deaths
were reported among patients with uAP. In AMI the
majority of cardiovascular death occurred in the first year
caused by cardiogenic shock or terminal heart failure,
whereas in uAP only 3 deaths occurred during this time.
The majority of cardiovascular death in uAP occurred after
1 year or later due to reinfarction, terminal heart failure
and sudden cardiac death. According to a receiver operat-
ing characteristic (ROC) analysis patients were catego-
rized into 2 groups: the high-TF activity group included
patients with TF values >24 pmol/L, the low TF activity
group included patients with TF values ≤ 24 pmol/L. ROC
– analysis revealed a substantial prognostic capability of
TF with an AUC of 0.66 (95%CI: 0.51 to 0.81). The clini-
cal characteristics of each patient group and the incidence
of cardiovascular death are shown in Table 1 and 2. As
expected, patients with AMI that died from cardiovascular
causes were older and had higher peak CK and NT-
proBNP levels at baseline than those that survived (data
not shown). Also, on admission they had a reduced left
ventricular ejection fraction and presented with a higher
Killip class. Patients with uAP that died had a higher prev-
alence of hypertension and preclinical resuscitation than
those that survived. No other characteristics were different
between patients that died and those that survived. The
majority of AMI patients received abciximab, and the
majority of uAP patients received only heparin.
TF activity and cardiovascular mortality
In patients with AMI the TF activity was 24.9+2.78 pmol/
L (mean+SEM) in survivors and 40.9+7.96 pmol/L in
nonsurvivors (P = 0.024). Kaplan-Meier estimates of sur-
vival regarding TF activity in AMI above or below 24 pmol
were 81.3% and 92.2% with an odds ratio of 3.02 (95%
CI [1.05–8.79], P = 0.03; Figure 1). In uAP no differences
in TF activity were observed in survivors and nonsurvivors
(25.7 ± 2.14 pmol/L versus 25.0 ± 8.04 pmol/L; P = 0.59).
The Cox proportional hazards model adjusting for corre-
lates of mortality showed that plasma TF activity was a
prognostic factor of mortality in patients with AMI
(Table 3).
Relationships between TF activity, inflammation, and 
necrosis
Among patients with AMI, TF activity correlated with
parameters of myocardial necrosis (peak CK: R = 0.22, P =
0.025; peak CK-MB: R = 0.23; P = 0.019; CK on admission:
R = 0.23, P = 0.037), Killip class (R = 0.22, P = 0.022), and
incidence of cardiopulmonary resuscitation on admission
(R = 0.20, P = 0.037). No association was found between
TF activity and markers of inflammation. In contrast,
among patients with uAP, TF activity was only correlated
with parameters of inflammation (CRP: R = 0.17, P  =
0.03; fibrinogen: R = 0.23, P = 0.005, and NT-proBNP: R
= 0.16, P = 0.035) but not with parameters of myocardial
necrosis, Killip class, or incidence of cardiopulmonary
resuscitation.
Sources of Circulating TF
To evaluate the functional significance and the underlying
sources of circulating TF, we performed a second study
comparing 36 patients with uAP and AMI and 28 control
patients with sAP. In contrast to patients with ongoing
ACS, almost no TF activity was detected in the circulation
of sAP patients (0.0 ± 0.0 pmol vs 0.5 ± 0.16 pmol, P =
0.008, Table 4), even after abrogating the endogenous
inhibition by TFPI-1 (0.98 ± 0.4 pmol vs 12.63 ± 1.82
pmol, P < 0.001).Thrombosis Journal 2009, 7:11 http://www.thrombosisjournal.com/content/7/1/11
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Currently there are two known sources that contribute to
circulating TF: alternatively spliced soluble TF (asTF) and
MP bearing membrane-bound TF. In order to analyze
both fractions we applied a differential centrifugation pro-
cedure, resulting in pellet and supernatant fractions. FACS
analysis showed the pellet was enriched in MP, while no
viable cell particles were found in the supernatant (Figure
2A, B, F, G). Nevertheless, both fractions contained com-
parable amounts of TF antigen (Figure 2C, H). We rea-
soned that the pellet fraction most likely represented
circulating MPs bearing TF, and the supernatant fraction
contained a soluble form of TF. The pellet fraction exhib-
ited a clear TF activity, which further increased after inhi-
bition of endogenous TFPI. However, the supernatant had
only little TF activity, devoid of any regulation by TFPI
(Figure 2D, I). No TF activity was detected in the superna-
tant using the assay for MP-bound TF activity (Figure 2E,
J). In the pellet, TF activity measured by the chromogenic
Table 1: Baseline characteristics of patients with acute myocardial infarction (n = 112)
Characteristic TF activity ≤ 24 pmol (n = 64) TF activity > 24 pmol (n = 48) P
TF Activity, (pmol) 7.0 ± 0.90 54.2 ± 3.30 <0.001
TF Activity + anti TFPI, (pmol) 39.7 ± 2.25 65.8 ± 2.99 <0.001
Demographics
Median age, years 64.5 ± 1.54 58.7 ± 1.95 0.02
Male sex 54 (84.4%) 37 (77.1%) 1.0
Number of CV death (n) 5 (7.8%) 11 (22.9%) 0.02
Time to death (days) 437.3 ± 145.72 218.0 ± 55.63 0.68
Days of follow up (days) 1460.0 ± 0.0 1460.0 ± 0.0 1.0
Pevious medical history
Myocardial infarction 15 (24.4%) 8 (16.7%) 0.005
ACVB 5 (7.8%) 2 (4.2%) 0.001
Cardiovascular risk factors
Arterial hypertension 40 (62.5%) 34 (70.8%) 0.17
Diabetes mellitus 14 (21.9%) 15 (31.3%) 0.001
Hypercholesterolemia 39 (60.9%) 25 (52.1%) 0.41
Current smoker 42 (65.6%) 36 (75.0%) 0.001
Biochemical markers
Peak creatine kinase, U/l 1475.0 ± 357.91 1897.7 ± 276.5 0.03
C-reactive protein, mg/dl 44.7 ± 11.22 26.2 ± 6.79 0.25
NT-pro-BNP, pg/ml 1739.4 ± 402.93 3946.8 ± 1442.53 0.28
Clinical data
Prehospital CPR 5 (7.8%) 10 (20.8%) 0.05
Cardiogenic shock 9 (14.1%) 13 (27.1%) 0.09
Killip's class
I 47 (73.4%) 25 (52.1%) 0.04
II 8 (12.5%) 10 (20.8%) 0.09
III 3 (4.7%) 6 (12.5%) 0.60
IV 6 (9.4%) 7 (14.6%) 0.40
Angiographic data
Left ventricular function 46.2 ± 1.56 45.3 ± 1.97 0.77
Target vessel
LAD 27 (42.2%) 29 (60.4%) 0.30
RCA 30 (46.9%) 12 (25.0%) 0.03
LCx 7 (10.9%) 7 (14.6%) 0.57
Extent of coronary artery
Disease
1-vessel-disease 18 (28.1%) 15 (31.3%) 0.72
2-vessel-disease 18 (28.1%) 14 (29.2%) 0.29
3-vessel-disease 28 (43.8%) 19 (39.6%) 0.16
Medication on admission
Aspirin 64 (100%) 48 (100%) 1.0
Heparin 12 (18.8%) 4 (8.3%) 0.07
Clopidogrel 54 (84.4%) 44 (91.7%) 0.83
Beta-Blockers 18 (28.1%) 10 (20.8%) 0.07
ACE-Inhibitors 10 (15.6%) 7 (14.6%) 0.86
Statins 12 (18.8%) 5 (10.4%) 0.85
ACVB: aortocoronary bypass grafting; CPR: cardiopulmonary resuscitationThrombosis Journal 2009, 7:11 http://www.thrombosisjournal.com/content/7/1/11
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and the MP assays were comparable, indicating that MPs
were a main component of plasma TF activity. In contrast,
in the supernatant, soluble forms of TF contributed to cir-
culating TF antigen, but possessed no TF activity and were
not regulated by TFPI. Flow cytometric characterization of
the MPs of patients with ACS revealed that circulating MPs
stained double-positive for platelet (CD41) and granulo-
cyte (CD66b) markers (Table 5). Among the MPs that
were Annexin+TF+, the percentages that were also
CD41+CD66b+ correlated with the basal TF activity.
Thus, in the plasma of patients with ACS, the TF activity
was a consequence of circulating MPs.
Discussion
This study shows that, the baseline plasma TF activity was
an independent predictor for cardiovascular death in
patients with AMI; furthermore, plasma TF activity was
correlated to parameters of myocardial necrosis. In con-
Table 2: Baseline characteristics of patients with unstable Angina pectoris (n = 174)
Characteristic TF activity ≤ 24 pmol (n = 106) TF activity > 24 pmol (n = 68) P
TF Activity, (pmol) 7.39 ± 0.60 53.9 ± 2.76 <0.001
TF Activity + anti TFPI, (pmol) 41.36 ± 1.92 66.17 ± 2.38 <0.001
Demographics
Median age, years 66.6 ± 1.05 67.2 ± 1.36 0.79
Male sex 76 (71.7%) 37 (54.4%) 0.88
Number of CV death (n) 10 (9.4%) 5 (7.4%)
Time to death (days) 655.47 ± 123.49 642.78 ± 137.90 0.93
Days of follow up (days) 1414.48 ± 11.24 1443.75 ± 8.39 0.13
Previous medical history
Myocardial infarction 35 (33.0%) 21 (30.9%) 0.74
ACVB 13 (12.3%) 7 (10.3%) 0.69
Cardiovascular risk factors
Arterial hypertension 91 (85.9%) 56 (82.4%) 0.54
Diabetes mellitus 28 (26.4%) 28 (41.2%) 0.07
Hypercholesterolemia 69 (65.1%) 40 (58.8%) 0.35
Current smoker 51 (48.1%) 30 (44.1%) 0.50
Biochemical markers
Peak creatine kinase, U/l 92.7 ± 5.39 188.2 ± 15.39 0.56
C-reactive protein, mg/dl 22.9 ± 4.00 24.8 ± 4.37 0.19
NT-pro-BNP, pg/ml 2321.24 ± 490.50 2176.1 ± 306.79 0.13
Clinical data
Prehospital CPR 1 (0.9%) 1 (1.5%) 0.75
Cardiogenic shock 2 (1.9%) 0 (0.0%) 0.26
Killip's class
I 103 (97.2%) 64 (94.1%) 0.32
II 2 (1.9%) 1 (1.5%) 0.84
III 0 (0.0%) 2 (2.9%) 0.08
IV 1 (0.9%) 1 (1.5.%) 0.75
Angiographic data
Left ventricular function 52.6 ± 1.38 51.5 ± 1.77 0.67
Target vessel
LAD 44 (41.5%) 33 (48.5%) 0.27
RCA 33 (31.1%) 24 (35.3%) 0.20
LCx 29 (27.4%) 11 (16.8%) 0.14
Extent of coronary artery
Disease
1-vessel-disease 21 (19.8%) 13 (19.1%) 0.90
2-vessel-disease 32 (30.2%) 21 (30.9%) 0.76
3-vessel-disease 53 (50.0%) 34 (50.0%) 0.85
Medication on admission
Aspirin 106 (100%) 68 (100.0%) 1.00
Heparin 63 (63.4%) 38 (55.9%) 0.79
Clopidogrel 91 (85.8%) 49 (72.1%) 0.54
Beta-Blockers 62 (58.5%) 38 (55.8%) 0.82
ACE-Inhibitors 53 (50.0%) 29 (42.7%) 0.34
Statins 44 (41.5%) 24 (35.3%) 0.46
ACVB: aorto-coronary bypass crafting; CPR: cardiopulmonary resuscitaionThrombosis Journal 2009, 7:11 http://www.thrombosisjournal.com/content/7/1/11
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trast, in patients with uAP, circulating TF activity was not
related to the long term prognosis.
This is the first study to address the issue of whether circu-
lating TF activity has an impact on cardiovascular mortal-
ity in patients with ACS. The associations between TF
antigen and cardiovascular risk have been extensively
studied with conflicting results. While some studies
involving ACS patients reported no association between
plasma TF levels and outcomes [18,19], others found TF
antigen to be an independent predictor of cardiovascular
events [12,14,16,17]. However TF antigen levels may not
adequately reflect the thrombogenic potential of circulat-
ing TF, [20,21]. Although we found a significant correla-
tion between TF antigen and TF activity (data not shown),
the indicative role of TF activity showed differences
among subpopulations. In patients with AMI, plasma TF
activity was significantly increased in those that died com-
pared to those that survived, while in patients with uAP
no such association was observed.
Sources of plasma TF include MP-associated TF, truncated
degradation products of TF, and the recently identified
alternatively spliced TF variant that lacks a transmem-
brane-domain [4]. Herein we demonstrate that plasma
membrane-bound TF was procoagulant, whereas soluble
TF was inactive and that circulating MPs constitute the
main reservoir of plasma TF activity. MPs have been
shown to emerge from atherosclerotic plaques, leuko-
cytes, platelets [22] and smooth muscle cells [23]. In AMI
TF activity was associated with markers of myocardial
necrosis. Since cardiomyocytes constitutively express TF
and release TF positive procoagulant MP under inflamma-
tory conditions, it is reasonable to speculate that MPs
bearing TF in ongoing AMI may arise from necrotic myo-
cardium [24,25]. MPs not only represent reliable hall-
marks of cell damage, but also influence endothelial
dysfunction, inflammation, and leukocyte adhesion
[26,27]. Consistent with previous studies TF activity in the
control group was below the assay's detection limit of 0.1
pM. [28]. The increase in TF activity observed in the
present study, might reflect a systemic hypercoagulable
state [29,30]. There is growing evidence that circulating TF
is potentially active in an encrypted state, where it can
bind FVII, but lacks proteolytic activity [31]. During
thrombosis, encrypted TF can become available [1].
Among the mechanisms that control encryption and
Table 3: Cox regression analysis for cardiovascular mortality in 
AMI patients in relation to risk factors
Significance Exp(B) 95%CI lower 95%CI upper
TF activity 0.03 9.27 1.24 69.12
Age 0.01 1.07 1.01 1.13
Hypertension 0.72 0.60 0.04 9.83
Diabetes 0.96 1.06 0.19 5.84
Smoking 0.96 0.97 0.31 3.03
Cholesterol 0.79 1.46 0.09 24.44
Kaplan-Meier cardiovascular mortality curves according to low and high TF activity in AMI Figure 1
Kaplan-Meier cardiovascular mortality curves according to low and high TF activity in AMI. Patients with AMI 
were divided in a group with high (> 24 pmol/L) and a group with low plasma TF activities on admission (≤ 24 pmol/L). (p = 
0,03).
TF activity <24 pmol
TF activity >24 pmolThrombosis Journal 2009, 7:11 http://www.thrombosisjournal.com/content/7/1/11
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decryption phosphatidyl serine exposure, calcium influx,
lipid raft dissociation, and Cys186–Cys209 disulfide forma-
tion appear to play a role [21,31-33]. The significance of
the present findings is supported by the fact that TF activ-
ity was an independent predictor for cardiovascular mor-
tality in AMI even after adjustment for possible
confounders. In accordance recent studies demonstrate,
that MP linked tissue factor activity is associated to fibri-
nolysis failure in ST segment elevation infarction and is
significantly elevated in the occluded coronary artery of
STEMI patients [34,35]. Although the clinical relevance of
circulating TF activity is still a matter of debate, our data
together with these publications underline the pathophys-
iological relevance of circulating TF in coronary athero-
thrombosis. However, it has to be stressed that the small
sample size limits the study due to low incidence of
deaths during the follow-up.
Table 4: Coagulation markers in patients with stable Angina pectoris and an additional population of patients with ACS
sAP (n = 28) ACS (n = 36) p
TF activity (pmol) 0.0 ± 0.0 0.5 ± 0.16 0.008
TF activity + anti-TFPI Ab (pmol) 0.98 ± 0.4 12.63 ± 1.82 <0.001
MP TF activity (nM) 0.24 ± 0.04 0.39 ± 0.07 0.03
Differential analysis of soluble TF (top row) and microparticle-associated TF (bottom row) in human plasma Figure 2
Differential analysis of soluble TF (top row) and microparticle-associated TF (bottom row) in human plasma. 
In both supernatant and pellet fractions, the frequencies of TF+Annexin+ microparticles were analyzed by FACS analysis. Rep-
resentative dot blots of a patient with ACS are shown with (A, F) light-scatter-staining, and (B, G) specific-staining. (C, H) Con-
centrations of TF antigen were measured by immunoassay. (D, I) Plasma TF activity with or without (+/-) anti-TFPI-1 was 
measured by FXa generation assay. (E, J) Specific microparticle-associated TF activity was measured following antibody capture 
of microparticles. Values are expressed as mean ± SEM.Thrombosis Journal 2009, 7:11 http://www.thrombosisjournal.com/content/7/1/11
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Our data corroborate the hypothesis that circulating TF
presents a high risk blood condition that is prone to
thrombosis. Therefore the plasma TF activity may serve as
a marker for dysregulated coagulation to predict athero-
thrombotic risk. Furthermore, pharmacological control of
plasma TF activity might reduce atherothrombotic risk.
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